[CAS NO. 2169232-81-7] Magrolimab
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [2169232-81-7]
Catalog
HY-P99029
Brand
MCE
CAS
2169232-81-7
DESCRIPTION [2169232-81-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Magrolimab] |
For research use only. We do not sell to patients.
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03869190 | Hoffmann-La Roche|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas |
Urothelial Carcinoma|Bladder Cancer
|
June 1, 2019 | Phase 1|Phase 2 |
| NCT03922477 | Hoffmann-La Roche |
Acute Myeloid Leukemia
|
October 8, 2019 | Phase 1 |
| NCT03248479 | Gilead Sciences |
Hematological Malignancies
|
September 8, 2017 | Phase 1 |
| NCT03527147 | Acerta Pharma BV|AstraZeneca |
NHL|DLBCL|Non-hodgkin´s Lymphoma|Diffuse Large B Cell Lymphoma
|
June 19, 2018 | Phase 1 |
| NCT04854499 | Gilead Sciences |
Head and Neck Squamous Cell Carcinoma
|
September 7, 2021 | Phase 2 |
| NCT04827576 | Gilead Sciences |
Solid Tumor
|
October 1, 2021 | Phase 2 |
| NCT02678338 | Gilead Sciences|California Institute for Regenerative Medicine (CIRM) |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
November 2015 | Phase 1 |
| NCT02953782 | Gilead Sciences|California Institute for Regenerative Medicine (CIRM) |
Solid Tumor|Colorectal Cancer
|
November 2, 2016 | Phase 1|Phase 2 |
| NCT05079230 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 7, 2022 | Phase 3 |
| NCT04541017 | National Cancer Institute (NCI) |
Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Sezary Syndrome|Refractory Mycosis Fungoides|Refractory Mycosis Fungoides and Sezary Syndrome|Refractory Sezary Syndrome|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
|
December 24, 2020 | Phase 1|Phase 2 |
| NCT04313881 | Gilead Sciences |
Myelodysplastic Syndromes
|
September 9, 2020 | Phase 3 |
| NCT02216409 | Gilead Sciences |
Solid Tumor
|
August 2014 | Phase 1 |
| NCT05330429 | Gilead Sciences |
Metastatic Colorectal Cancer
|
July 8, 2022 | Phase 2 |
| NCT04788043 | Stanford University|Merck Sharp & Dohme LLC |
Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Relapsed Classical Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma
|
June 21, 2022 | Phase 2 |
| NCT04751383 | National Cancer Institute (NCI) |
High Risk Neuroblastoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Refractory Neuroblastoma|Resectable Osteosarcoma
|
April 16, 2021 | Phase 1 |
| NCT02953509 | Gilead Sciences|The Leukemia and Lymphoma Society |
Non Hodgkin Lymphoma
|
November 21, 2016 | Phase 1|Phase 2 |
| NCT04599634 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Lymphoma|B-Cell Lymphoma
|
December 16, 2021 | Phase 1 |
| NCT04778410 | Gilead Sciences |
Myeloid Malignancies
|
June 28, 2021 | Phase 2 |
| NCT03558139 | Gilead Sciences|Merck KGaA, Darmstadt, Germany |
Ovarian Cancer
|
May 23, 2018 | Phase 1 |
| NCT04778397 | Gilead Sciences |
Acute Myeloid Leukemia
|
July 1, 2021 | Phase 3 |
| NCT05169944 | University of California, San Francisco|Gilead Sciences |
Brain Cancer|Malignant Brain Tumor|Recurrent Brain Tumor|Progressive Malignant Brain Tumor|Brain Tumor, Pediatric|Brain Tumor Adult
|
April 22, 2022 | Phase 1 |
| NCT05367401 | Novartis Pharmaceuticals|Novartis |
Myelodysplastic Syndromes|Acute Myeloid Leukemia
|
December 20, 2024 | Phase 1|Phase 2 |
| NCT04958785 | Gilead Sciences |
Triple-Negative Breast Cancer
|
December 14, 2021 | Phase 2 |
| NCT04435691 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Acute Myeloid Leukemia|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
July 28, 2020 | Phase 1|Phase 2 |
| NCT04892446 | Gilead Sciences |
Multiple Myeloma
|
November 9, 2021 | Phase 2 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.